Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Neurology›Clinical Question·Updated Jul 3, 2026·v1

First-line pharmacological treatment for acute migraine

First-line pharmacological treatment for acute [[migraine in adults]] prioritizes [[triptans]], either as monotherapy or in combination with [[nonsteroidal anti-inflammatory drugs]] (NSAIDs) [6, 9]. [[Eletriptan]] is the most effective oral monotherapy for achieving pain freedom at 2 hours (OR 5.19, 95% CI 4.25-6.33) [9]. For pediatric

Moderate Evidence20 references·1,664 words·7 min read·v1
First-line pharmacological treatment for acute [[migraine in adults]] prioritizes [[triptans]], either as monotherapy or in combination with [[nonsteroidal anti-inflammatory drugs]] (NSAIDs) [6, 9]. [[Eletriptan]] is the most effective oral monotherapy for achieving pain freedom at 2 hours (OR 5.19, 95% CI 4.25-6.33) [9].

Board Review — High Yield

  • •Eletriptan is the most effective oral monotherapy for 2-hour pain freedom in adults.
  • •Triptans, specifically eletriptan and rizatriptan, replaced ergotamines as the efficacy standard for acute migraine relief.
  • •[[Eletriptan]] provides the highest odds of 2-hour pain freedom among oral monotherapies (OR 5.19).
  • •Rimegepant 75 mg is a primary alternative for patients with cardiovascular contraindications to triptans.
  • •Ubrogepant and atogepant show comparable efficacy in both male and female patients [18].

Deep Dive — Evidence Details

References

  1. [1]

    Oskoui M, Pringsheim T, Holler-Managan Y et al.. “Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.” Neurology (2019). PMID: 31413171 ↗

    L2GUIDELINECited in: Bottom Line
  2. [2]

    Venkatesan T, Levinthal DJ, Tarbell SE et al.. “Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association.” Neurogastroenterology and motility (2019). PMID: 31241819 ↗

    L2GUIDELINECited in: Bottom Line
  3. [3]

    Khodeer DM, Abdelmonem SM, Dossouvi KM et al.. “Efficacy and safety of rimegepant for acute and preventive treatment of migraine: a systematic review and meta-analysis of randomized controlled trials.” BMC pharmacology & toxicology (2026). PMID: 42152069 ↗

    L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  4. [4]

    Liao YC, Chen WS, Restya WPD et al.. “Effectiveness and influence of mindfulness-based intervention on migraine patients: A systematic review and meta-analysis.” Journal of psychosomatic research (2025). PMID: 40876377 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  5. [5]

    Tessitore A, Zupin L, Celsi F et al.. “Ketorolac use in the emergency department in children: a systematic review and meta-analysis.” European journal of pediatrics (2025). PMID: 40229463 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  6. [6]

    Gartlehner G, Dobrescu A, Wagner G et al.. “Pharmacologic Treatment of Acute Attacks of Episodic Migraine: A Systematic Review and Network Meta-analysis for the American College of Physicians.” Annals of internal medicine (2025). PMID: 40096693 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  7. [7]

    Laohapiboolrattana W, Jansem P, Anukoolwittaya P et al.. “Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis.” The journal of headache and pain (2024). PMID: 39516789 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  8. [8]

    Aderinto N, Olatunji G, Kokori E et al.. “Prevalence, characteristics, and treatment outcomes of migraine headache in Nigeria: a systematic review and meta-analysis.” The journal of headache and pain (2024). PMID: 39379798 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  9. [9]

    Karlsson WK, Ostinelli EG, Zhuang ZA et al.. “Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.” BMJ (Clinical research ed.) (2024). PMID: 39293828 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  10. [10]

    Khoo CC, Liu CC, Lu M et al.. “Acute and preventive treatment of menstrual migraine: a meta-analysis.” The journal of headache and pain (2024). PMID: 39227797 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  11. [11]

    Sirilertmekasakul C, Panto A, Lekhalawan P et al.. “The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2024). PMID: 38564060 ↗

    L2SR_OBSCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  12. [12]

    Ashina M, McAllister P, Gaul C et al.. “Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.” Cephalalgia : an international journal of headache (2025). PMID: 41255093 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  13. [13]

    Turan Y, Akoglu H, Unal E et al.. “Efficacy of Adding Intravenous Saline Solution to Nonsteroidal Anti-Inflammatory Drug-Based Treatment of Acute Migraine in the Emergency Department.” Annals of emergency medicine (2025). PMID: 41071134 ↗

    L1RCTCited in: Current Evidence and Standard
  14. [14]

    Gryglas-Dworak A, Schim J, Ettrup A et al.. “Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial.” Headache (2024). PMID: 39501727 ↗

    L1RCTCited in: Current Evidence and Standard
  15. [15]

    Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I et al.. “Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians.” Annals of internal medicine (2025). PMID: 39899861 ↗

    L2GUIDELINECited in: On the Horizon
  16. [16]

    Sico JJ, Antonovich NM, Ballard-Hernandez J et al.. “2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache.” Annals of internal medicine (2024). PMID: 39467289 ↗

    L2GUIDELINECited in: On the Horizon
  17. [17]

    Makita LM, Fagundes TP, Reginato PH et al.. “Estimating Changes in Clinical Outcomes after Discontinuation of Anti-CGRP Targeting Therapy for Migraine Prophylaxis: A Systematic Review and Meta-analysis.” CNS drugs (2025). PMID: 41026450 ↗

    L2SR_OBSCited in: On the Horizon
  18. [18]

    Goadsby PJ, Jürgens TP, Brand-Schieber E et al.. “Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials.” Cephalalgia : an international journal of headache (2025). PMID: 39982105 ↗

    L2SR_OBSCited in: On the Horizon
  19. [19]

    Damen JAA, Yang B, Idema DL et al.. “Comparative Effectiveness of Pharmacologic Treatments for the Prevention of Episodic Migraine Headache: A Systematic Review and Network Meta-analysis for the American College of Physicians.” Annals of internal medicine (2025). PMID: 39899873 ↗

    L2SR_OBSCited in: On the Horizon
  20. [20]

    Al-Khazali HM, Ashina H, Christensen RH et al.. “Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab.” Cephalalgia : an international journal of headache (2024). PMID: 38859744 ↗

    L1RCTCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…